Associate Professor of Hepatopancreatobiliary Surgery and Scientist
Université de Montréal
Dr. Turcotte is a Canadian surgeon-scientist with bench-to-bedside expertise in solid cancer immunology and T cell immunotherapy. After his general surgery training in cancer immunology at Université de Montréal, he completed a post-doctoral training at the National Cancer Institute and at the Memorial Sloan Kettering Cancer Center, focusing on the immune recognition of metastatic gastrointestinal cancers. During those years, he established that endogenous T cells could recognize antigens derived from tumour mutations in gastrointestinal cancers refractory to chemotherapy, and that these reactive T cells could be effectively used for cell therapy.
Since 2013, he is a professor at the Université de Montréal, works as a hepatopancreatobiliary (HPB) surgical oncologist and as a scientist at the Centre hospitalier de l’Université de Montréal (CHUM). His laboratory focuses on characterizing the features of neoantigen-reactive tumour-infiltrating T lymphocytes (TIL), what inhibit those cells specifically in HPB cancers and the development of novel immune-based biomarkers for metastatic colorectal cancer. He is the Medical Director of the CHUM Unit for cell production enabling TIL manufacturing in early phase trials. He is leading the T cell immunotherapy clinical research program for patients with solid cancers at the CHUM. He leads one of the largest HPB cancer biobank and prospective database in Canada.
How should we use ctDNA to Treat Patients with Advanced Colon and Pancreatic Cancer?
Friday, March 22, 2024
11:30am – 12:00pm ET